Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Pharmaceutical firm Celgene has invested an undisclosed amount in US-based immunometabolic cancer drug developer Kyn Therapeutics as part of a strategic collaboration deal that will also involve an upfront payment of $80m. Kyn had previously received $49m in series A funding from healthcare investment firm OrbiMed and venture capital firm Atlas Venture in December 2017.

Farewill, the UK-based operator of an online will preparation service, has secured £7.5m ($9.6m) in funding from investors including DMG Ventures, the venture capital arm…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.